主页 > 医学前沿 >
【drug-news】循证医学证实曲妥单抗结合化疗提高
http://www.sciencedaily.com/releases/2007/07/070707083310.htm
Science Daily — A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.
All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.
Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.
The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.
"Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities", Dahabreh said.
This is the first meta-analysis of current published trials on the adjuvant use of trastuzumab. The results are of great clinical value since they indicate that treatment with trastuzumab results in major survival benefit in women with an aggressive disease subtype.
The level of effectiveness demonstrated by this analysis is largely unprecedented in the treatment of solid tumors, the authors say, and highlights the potential of implementing targeted agents with cytotoxic chemotherapy. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 初译：
Title:Analysis Confirms Benefits Of Combining Trastuzumab And Chemotherapy
题目：循证医学证实曲妥单抗结合化疗提高乳腺癌治疗效果
Science Daily — A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
据科学日报报道，最近对五项乳腺癌试验的meta分析证实，曲妥单抗结合化疗可提高HER-2阳性乳腺癌妇女的存活率。
At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.
在Lugano召开的欧洲临床肿瘤学学会会议上，来自Athens大学的Issa Dahabreh报道了对五项乳腺癌试验的meta分析的结果，这五个试验包括了13000多名已进行外科治疗的女性乳腺癌患者。
All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.
所有试验均比较了女性乳腺癌患者在术后仅进行辅助化疗或化疗联合曲妥单抗在无病存活期、总存活期及近期和远期复发风险方面的差异。
Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.
在所有乳腺癌患者中，有共计1/4患者表达高水平的HER2蛋白或含有多拷贝的HER2基因。此类肿瘤似乎与疾病的侵袭力、高复发的可能性及治疗反应的降低更加相关。曲妥单抗是一种直接针对HER2酪氨酸激酶受体的单抗。
The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.
Dahabreh说，此结果显示曲妥单抗结合化疗可使病死率下降34％，无病存活率升高38％。不仅存活率有所改善，而且肿瘤近期和远期复发风险也同时降低。
"Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities", Dahabreh said.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-16 17:12
医学,生命科学网